Clinical Trials › NCT06408259
RecruitingPhase 3
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Sponsored by Celgene
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 194
Target enrollment
9
U.S. states
Apr 2025
Start date
Jul 2036
Expected completion
Interventions / Treatments
OzanimodFingolimodPlacebo
Conditions studied
Multiple Sclerosis, Relapsing-Remitting
Where this trial is running (12 sites)
California2 sites
Loma Linda · Sacramento
Illinois2 sites
Chicago · Chicago
New Jersey2 sites
New Brunswick · Teaneck
Florida1 site
Tampa
Kentucky1 site
Louisville
Ohio1 site
Cincinnati
Oregon1 site
Portland
Texas1 site
El Paso
Wisconsin1 site
Milwaukee
Participating MS centers on MS Buddy (6)
UC Davis Health MS Program
Sacramento, CA
Sacramento, CA
USF Multiple Sclerosis Center
Tampa, FL
Tampa, FL
University of Chicago MS Clinic
Chicago, IL
Chicago, IL
Providence Multiple Sclerosis Center
Portland, OR
Portland, OR
MS centers in California
Compare treatment centers near a trial site by center type, providers and trials.
View California centersMore Phase 3 trials
Browse all Phase 3 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.